Table C-13. Risk of bias of mattress cover randomized controlled trials

| Study | Sequence Generation | Allocation Concealment | Blinding Participants and Personnel | Blinding Outcome Assessors | Incomplete Outcome Data | Selective Outcome Reporting | Other Sources of Bias | Overall Risk of Bias | Comments |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Murray et al.201718 | Low | Low | Low | Low | Low | Low | Low | Low | Placebo; patients and assessors blinded; 15% attrition; intent-to-treat analysis; pre-specified outcomes reported |
| Tsurikisawa et al. 201619 | Unclear | Unclear | High | Unclear | High | Low | Low | High | Insufficient description of randomization; patients not blinded; unclear if outcome assessors were blinded; 23% attrition; no intent-to-treat analysis |
| Tsurikisawa et al. 201320 | Unclear | Unclear | High | High | Low | Low | Low | Medium | Insufficient description of randomization; no blinding; all patients completed study |
| Glasgow et al. 201121 | Low | Low | Low | Low | Low | Low | Low | Low | Placebo; patients and assessors blinded; low attrition; intent-to-treat analysis; pre-specified outcomes reported |
| Nambu et al. 200822 | Unclear | Unclear | Low | Low | Low | Low | Low | Low | Insufficient description of randomization; placebo; patients and assessors blinded; all patients completed study |
| de Vries et al. 200723 | Low | Low | Low | Low | Unclear | Low | Low | Low | Placebo; patients blinded and most outcomes patient-reported; moderate attrition rate of 17% but intent-to-treat analysis used; pre-specified outcomes reported; study funded in part by pharmaceutical manufacturers |
| Dharmage et al. 200625 | Low | Low | Low | Low | Low | Low | Low | Low | Placebo; participants and assessors blinded; low attrition; pre-specified outcomes reported |
| van den Bemt et al. 200426 | Unclear | Unclear | Low | Low | Low | High | Low | Medium | Insufficient description of randomization; placebo; patients blinded and most outcomes patient-reported; intent-to-treat analysis used; did not report followup symptom score because baseline scores were very low |
| Halken et al. 200327 | Low | Low | Low | Low | High  | Low | Low | Medium | Placebo; participants and assessors blinded; 17% attrition  |
| Lee 200328 | Unclear | Unclear | High | High | High | High | Low | High | Insufficient description of randomization; no placebo; no blinding; 30% attrition |
| Luczynska et al. 200329 | Unclear | Unclear | Low | Low | Low | Low | Low | Low | Insufficient description of randomization; placebo; patients blinded and most outcomes patient-reported; intent-to-treat analysis found similar results; pre-specified outcomes reported |
| Woodcock et al. 200330 | Low | Low | Low | Low | Low | Low | Low | Low | Placebo; participants and assessors blinded; 16% attrition;  |
| Rijssenbeek-Nouwens et al. 200231 | Unclear | Unclear | Low | Low | High | Low | Low | Medium | Insufficient description of randomization; placebo; patients blinded and most outcomes patient-reported; 21% attrition with no apparent intent-to-treat analysis; pre-specified outcomes reported |
| Sheikh et al. 200232 | Low | Low | Low | Low | Low | Low | Low | Low | Placebo; participants and assessors blinded; low attrition; pre-specified outcomes reported |
| Frederick et al. 199733 | Unclear | Unclear | Low | High | Unclear | Low | High | High | Insufficient description of randomization; patients only blinded; attrition not described; pre-specified outcomes reported; 3/5 authors funded or employed by relevant industry |
| Burr et al. 198034 | Unclear | Unclear | High | High | Low | High | Low | High | Insufficient description of randomization; no blinding; no placebo; attrition not described, very few outcomes reported |
| Burr et al. 197635 | Unclear | Unclear | High | High | Unclear | High | Low | High | Insufficient description of randomization; no blinding; no placebo; attrition not described, very few outcomes reported |